Energy dependence and dose response of Gafchromic EBT2 film over a wide range of photon, electron, and proton beam energies

2010 ◽  
Vol 37 (5) ◽  
pp. 1942-1947 ◽  
Author(s):  
Bijan Arjomandy ◽  
Ramesh Tailor ◽  
Aman Anand ◽  
Narayan Sahoo ◽  
Michael Gillin ◽  
...  
2010 ◽  
Vol 37 (6Part21) ◽  
pp. 3265-3265 ◽  
Author(s):  
A Anand ◽  
B Arjomandy ◽  
R Tailor ◽  
N Sahoo ◽  
M Gillin

2011 ◽  
Vol 38 (6Part13) ◽  
pp. 3524-3525
Author(s):  
S Park ◽  
S Kang ◽  
K Cheong ◽  
T Hwang ◽  
M Lee ◽  
...  

2013 ◽  
Vol 40 (6Part10) ◽  
pp. 212-212
Author(s):  
W Chen ◽  
X Di ◽  
S Wang ◽  
B Wang ◽  
X Bai ◽  
...  

HortScience ◽  
1997 ◽  
Vol 32 (3) ◽  
pp. 436E-436
Author(s):  
Martin P.N. Gent

The persistence of effects of paclobutrazol or uniconazol on stem elongation was determined for several years after large-leaf Rhododendron and Kalmia latifolia were treated with a single-spray application of these triazol growth-regulator chemicals. Potted plants were treated in the second year from propagation, and transplanted into the field in the following spring. The elongation of stems was measured in the year of application and in the following 2 to 4 years. Treatments with a wide range of doses were applied in 1991, 1992, or 1995. For all except the most-dilute applications, stem elongation was retarded in the year following application. At the highest doses, stem growth was inhibited 2 years following application. The results could be explained by a model of growth regulator action that assumed stem elongation was inversely related to amount of growth regulator applied. The dose response coefficient for paclobutrazol was less than that for uniconazol. The dose that inhibited stem elongation one-half as much as a saturating dose was about 0.5 and 0.05 mg/plant, for paclobutrazol and uniconazol, respectively. The dose response coefficient decreased exponentially with time after application, with an exponential time constant of about 2/year. The model predicted a dose of growth regulator that inhibited 0.9 of stem elongation immediately after application would continue to inhibit 0.5 of stem elongation in the following year.


Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1889
Author(s):  
Arthur Bongrand ◽  
Charbel Koumeir ◽  
Daphnée Villoing ◽  
Arnaud Guertin ◽  
Ferid Haddad ◽  
...  

Proton therapy (PRT) is an irradiation technique that aims at limiting normal tissue damage while maintaining the tumor response. To study its specificities, the ARRONAX cyclotron is currently developing a preclinical structure compatible with biological experiments. A prerequisite is to identify and control uncertainties on the ARRONAX beamline, which can lead to significant biases in the observed biological results and dose–response relationships, as for any facility. This paper summarizes and quantifies the impact of uncertainty on proton range, absorbed dose, and dose homogeneity in a preclinical context of cell or small animal irradiation on the Bragg curve, using Monte Carlo simulations. All possible sources of uncertainty were investigated and discussed independently. Those with a significant impact were identified, and protocols were established to reduce their consequences. Overall, the uncertainties evaluated were similar to those from clinical practice and are considered compatible with the performance of radiobiological experiments, as well as the study of dose–response relationships on this proton beam. Another conclusion of this study is that Monte Carlo simulations can be used to help build preclinical lines in other setups.


1990 ◽  
Vol 8 (6) ◽  
pp. 1070-1082 ◽  
Author(s):  
J M Kirkwood ◽  
M S Ernstoff ◽  
T Trautman ◽  
G Hebert ◽  
Y Nishida ◽  
...  

Interferon-gamma (IFN gamma), as produced by recombinant DNA technology, has shown a wide range of immunomodulatory activity in vitro and in vivo. Clinical studies have attempted to establish a dose-response relationship to define optimal dosage ranges for induction of effector cell function and host response in patients with cancer. We conducted a randomized trial to test the in vivo biologic activity of five daily dosages ranging from 3 to 3,000 micrograms/m2, administered by daily 2-hour bolus injection or by continuous infusion for 14 days. We demonstrate comparable immunobiologic effects of recombinant IFN gamma (rIFN gamma; Biogen, Inc, Cambridge, MA) administered by these two schedules at the various dosages tested, and have defined a relationship of dose to biologic response over this 3-log10 dose range. Oligo 2'5' adenylate synthetase (2'5'As) induction, natural-killer (NK) cell activity, and T-cell subset distribution (heightened T helper/suppressor ratio) showed the most consistent treatment-associated changes and the greatest immunobiologic effects at dosages of 300 to 1,000 micrograms/m2. Mononuclear cell DR and DQ antigen expression showed no consistent dose-related treatment effect. The relevance of the phenotypic, functional, and enzymologic effects observed in this trial to any clinical antitumor effects of IFN gamma in cancer therapy must now be established.


2012 ◽  
Vol 39 (6Part11) ◽  
pp. 3730-3730
Author(s):  
G Massillon-JL ◽  
I Domingo-Muñoz ◽  
P Díaz-Aguirre

Sign in / Sign up

Export Citation Format

Share Document